Deerfield Management’s Faeth Therapeutics FTH Stock Holding History

Deerfield Management’s Portfolio FTH Stock Details FTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-18,750	Closed	-$5.45M	–	155
2021 Q1	$5.45M	Buy	+18,750	New	+$6.28M	0.11%	118

Other funds holding FTH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCM

Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Formula Growth Montreal, Quebec, Canada $222M AUM 27.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management's FTH Position: Q2 2021 in Review

Deerfield Management sold out of Faeth Therapeutics (FTH) in Q2 2021, closing a stake of 18,750 shares — an estimated $5.45M sold.

Deerfield Management first reported a position in FTH in Q1 2021 and held it in 1 quarter. The position peaked at $5.45M in Q1 2021. 34 funds tracked by Wall St. Rank hold FTH as of Q2 2021.

Deerfield Management reported no remaining Faeth Therapeutics position as of Q2 2021 after selling out during the quarter.
Deerfield Management sold 18,750 Faeth Therapeutics shares in Q2 2021, an estimated $5.45M.
Deerfield Management first reported a position in Faeth Therapeutics in Q1 2021 and held it in 1 quarter.
Deerfield Management's Faeth Therapeutics position peaked at $5.45M in Q1 2021.
34 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2021.

Based on Deerfield Management's 13F filing for Q2 2021, filed 16 Aug 2021.